Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy

Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy

Objective: Systemic anaplastic large cell lymphoma (sALCL) is a rare and severe non-Hodgkin lymphoma. Despite its clinical relevance, the aetiology of this disease is unknown, not allowing the patient to prevent and counteract it. This study investigates the cost-effectiveness of Brentuximab Vedoti...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andrea Marcellusi, Chiara Bini, Laura Fioravanti, Silvia Ripoli, Paolo Morelli
Format:	Article
Language:	English
Published:	AboutScience Srl 2025-04-01
Series:	Global & Regional Health Technology Assessment
Subjects:	Brentuximab Vedotin Cost-effectiveness analysis economic evaluation sALCL Systemic anaplastic large cell lymphoma
Online Access:	https://journals.aboutscience.eu/index.php/grhta/article/view/3306
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study
by: Zhiqiang Zhao, et al.
Published: (2025-01-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

PRIMARY PALATAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: RARITY TREATED SUCCESSFULLY WITH BRENTUXIMAB VEDOTIN
by: Müjgan Çözeli, et al.
Published: (2024-12-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas
by: Gen Hasegawa, et al.
Published: (2025-01-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials
by: Yue Yang, et al.
Published: (2025-07-01)

Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion
by: Ellen Marin, et al.
Published: (2025-02-01)

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
by: Carrie van der Weyden, et al.
Published: (2025-06-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)

CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
by: Dody Ranuhardy, et al.
Published: (2018-06-01)

CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
by: Dody Ranuhardy, et al.
Published: (2018-06-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

Neoadjuvant Immunotherapy and De-escalation of Surgery in Locally Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma
by: Marzia Salgarello, et al.
Published: (2025-01-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Comprehensive study of anaplastic large cell lymphoma: clinicopathological features from Indonesia
by: Agnes Stephanie Harahap, et al.
Published: (2025-07-01)

SYSTEMATIC REVIEW: ANAPLASTIC LARGE CELL LYMPHOMA FOLLOWING BREAST IMPLANT SURGERY
by: Kezia Eveline, et al.
Published: (2023-06-01)

An Isolated Cutaneous Relapse in a Known Case of Systemic ALK-Positive Anaplastic Large Cell Lymphoma: A Rare Case Report with Review of Literature
by: Monisha Shetty, et al.

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS
by: A. S. Kolbin, et al.
Published: (2017-05-01)

First Case Report of Breast Implant Associated-Anaplastic Large Cell Lymphoma from India: Are We Ready?
by: Soumya Khanna, et al.
Published: (2023-04-01)

Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient
by: Adela Della Marina, et al.
Published: (2025-06-01)

Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
by: Astrid Pavlovsky, et al.
Published: (2024-12-01)

Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation
by: Abeer Ezzat, et al.
Published: (2025-01-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Case Report: Vanishing bile duct syndrome in Hodgkin’s lymphoma: a case highlighting jaundice and lymphadenopathy as early clues
by: Shiyu Ma, et al.
Published: (2025-05-01)

Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre studyResearch in context
by: Yu-Jia Huo, et al.
Published: (2025-05-01)

A Rare Case of Anaplastic Lymphoma Kinase-negative Anaplastic Large Cell Lymphoma Presenting as Right Heart Failure
by: U. Harikishore, et al.
Published: (2025-01-01)

Hematopoietic Stem Cell Transplantation and High Dose Chemotherapy in Recurrent and/or Chemotherapy Resistant Hodgkin Lymphoma Cases: A Single Center Experience
by: Yöntem Yaman, et al.
Published: (2021-05-01)

Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma
by: Zhongqing Zou, et al.
Published: (2025-07-01)

Correction: Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma
by: Zhongqing Zou, et al.
Published: (2025-08-01)

Primary Breast Anaplastic Large-Cell Lymphoma
by: Min-Hong Wang, et al.
Published: (2023-10-01)

Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China
by: Mengya Li, et al.
Published: (2025-08-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
by: E. V. Chernyshova, et al.
Published: (2017-01-01)

An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review
by: Shu-Cheng Wu, et al.
Published: (2024-01-01)

Modern Aspects of Diagnosis and Treatment of Anaplastic Large Cell Lymphoma in Children (Literature Review)
by: AS Levashov, et al.
Published: (2016-04-01)

Breast implant-associated anaplastic large-cell lymphoma: a systematic literature review
by: Daniel Sundfeld Spiga Real, et al.
Published: (2019-12-01)

Anaplastic meningioma to supraclavicular lymph node with malignant B cell lymphoma: A rare case report
by: Shrinjay Vyas, et al.
Published: (2025-06-01)